Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 3
2007 2
2008 1
2013 2
2014 2
2015 1
2016 5
2017 14
2018 13
2019 15
2020 19
2021 23
2022 22
2023 12
2024 22
2025 18
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Results by year

Filters applied: . Clear all
Page 1
Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017.
Tanaka K, Shimomura A, Ishitobi M, Yamanaka T, Tsukioki T, Iwata H, Hara F, Fujisawa T, Sasaki K, Sadachi R, Kajikawa R, Sakai T, Sagara Y, Shigematsu H, Ozaki Y, Nozawa K, Sudo K, Naito Y, Terata K, Ishiba T, Fukuda H, Shien T. Tanaka K, et al. Among authors: shimomura a. Breast Cancer. 2026 Apr 16. doi: 10.1007/s12282-026-01846-3. Online ahead of print. Breast Cancer. 2026. PMID: 41989526 No abstract available.
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.
Dent R, Shao Z, Schmid P, Cortes J, Cescon DW, Saji S, Jung KH, Bachelot T, Wang S, Ramírez EM, Basaran G, Stradella A, Mathiba R, Chen SC, Shen K, Wéber Á, Battelli N, Niikura N, Luo T, Chae YS, Fischbach N, Garbaos G, Patera A, Zhao K, Vuković P, Maxwell MJ, Traina T; TROPION-Breast02 investigators. Dent R, et al. Ann Oncol. 2026 Apr 3:S0923-7534(26)00130-4. doi: 10.1016/j.annonc.2026.03.008. Online ahead of print. Ann Oncol. 2026. PMID: 41937088 Free article.
Efficacy and prognostic predictors of primary systemic therapy for de novo Stage IV breast cancer. Exploratory analysis of JCOG1017 PRIM-BC.
Shien T, Ishitobi M, Sasaki K, Tanaka K, Shimomura A, Tsukioki T, Sagara Y, Kimura Y, Terata K, Ishiba T, Yasojima H, Ono M, Goda K, Naito Y, Fujisawa T, Hara F, Ogawa G, Fukuda H, Iwata H; Breast Cancer Study Group of Japan Clinical Oncology Group (JCOG), Japan. Shien T, et al. Among authors: shimomura a. Breast Cancer. 2026 Mar;33(2):396-406. doi: 10.1007/s12282-025-01821-4. Epub 2026 Jan 31. Breast Cancer. 2026. PMID: 41619104 Free PMC article.
A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110).
Sasaki K, Ishiba T, Nishibuchi I, Hara F, Sekino Y, Machida R, Shibata T, Kawahara D, Sagara Y, Naito Y, Terata K, Ozaki Y, Shimomura A, Sakai T, Shigematsu H, Sudo K, Nozawa K, Yoshimura M, Shikama N, Mizowaki T, Shien T. Sasaki K, et al. Among authors: shimomura a. Jpn J Clin Oncol. 2026 May 7;56(5):659-665. doi: 10.1093/jjco/hyag019. Jpn J Clin Oncol. 2026. PMID: 41615067 Clinical Trial.
Clinical complete response and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy aimed at omission of surgery: an exploratory analysis of the JCOG1806 trial.
Shigematsu H, Fujisawa T, Hara F, Iwata H, Ishiba T, Ozaki Y, Sakai T, Sagara Y, Shimomura A, Sudo K, Terata K, Naito Y, Nozawa K, Sasaki K, Mitome N, Sadachi R, Shibata T, Shien T. Shigematsu H, et al. Among authors: shimomura a. Int J Clin Oncol. 2026 Mar;31(3):528-536. doi: 10.1007/s10147-026-02967-7. Epub 2026 Jan 22. Int J Clin Oncol. 2026. PMID: 41572060 Free PMC article.
Germline variants of the POLH and RAD51 genes are candidate variants associated with risk of hormone receptor-negative young-onset breast cancer.
Yazaki S, Kitadai R, Momozawa Y, Yoshida T, Yamanaka T, Shiino S, Yamauchi C, Harano K, Saito M, Hirotsu Y, Aiba H, Hamamoto R, Shimizu C, Shimomura A, Shimoi T, Sudo K, Yoshida M, Sunami K, Shiraishi Y, Kuchiba A, Hori M, Katanoda K, Takata S, Ogawa A, Torasawa M, Mochizuki A, Shimada Y, Hiranuma K, Fujii E, Hirata M, Yamashita Y, Kogawa T, Murata T, Fujiwara S, Miyagi Y, Nakagomi H, Tachibana K, Matsuda K, Murakami Y, Tokunaga K, Kawai Y; NCBN Controls WGS Consortium; Project BJ, Omata M, Ohtake T, Suto A, Onishi T, Naito Y, Yamashita T, Yonemori K, Kohno T, Shiraishi K. Yazaki S, et al. Among authors: shimomura a. NPJ Breast Cancer. 2025 Nov 28;11(1):133. doi: 10.1038/s41523-025-00848-2. NPJ Breast Cancer. 2025. PMID: 41315479 Free PMC article.
161 results